Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Condylomata Acuminata 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Omiganan × Clear all
NCT02596074 2017-08-03

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Maruho Co., Ltd.

Phase 2 Completed
12 enrolled

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

NCT02849262 2017-03-31

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Maruho Co., Ltd.

Phase 2 Completed
24 enrolled

Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡